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P U B L I S H E D B Y E L S E V I E R I N C .LettersTicagrelor Crushed
Tablets Administration in
STEMI Patients
The MOJITO StudyIn healthy volunteers, 300 mg clopidogrel adminis-
tered crushed via a nasogastric tube results in faster
and greater bioavailability of the drug compared with
whole tablets administered orally (1). Recently, Crean
et al. (2) reported that ticagrelor tablets could be
easily crushed and prepared for oral and nasogastric
tube administration, delivering the full dose of the
original tablet.
The MOJITO (Mashed Or Just Integral pill of
TicagrelOr) study was a prospective, 4-center, inter-
national, randomized, active-controlled study with
the aim to evaluate the superiority of ticagrelor
crushed pills versus integral tablets of equal dose in
decreasing platelet reactivity in P2Y12-naive, ST-
segment elevation myocardial infarction (STEMI) pa-
tients undergoing primary percutaneous coronary
intervention. The local ethics committee approved the
study, which was registered on ClinicalTrials.gov
(NCT01992523). All patients gave informed consent.
Following exclusions, 82 patients were randomized to
either a crushed ticagrelor 180-mg loading dose (LD) or
oral integral tables of equal dose before primary
percutaneous coronary intervention. Crushed tablets
were prepared placing 2 ticagrelor pills in a mortar and
mashing for 60 s using a pestle (2). The total contents of
the mortar was transferred to the dosing cup, 50 ml of
puriﬁed water was added, and the suspension was
mixed up before drinking. Platelet function testing
was performed with VerifyNow (Accumetrics, San
Diego, California) at baseline and at 1, 2, 4, and 8 h,
and the results are reported in P2Y12 reaction units
(PRU) (3). High-platelet reactivity (HPR) was deﬁned
as a PRU >208. The primary endpoint was PRU 1 h
after LD.
A forward stepwise binary logistic regression
analysis was used to evaluate the independent
contribution of clinical characteristics to HPR at 1 h
with certain variables entered into the model,
including age (years), body mass index, diabetesmellitus, morphine use, baseline PRU value, and
ticagrelor crushed pills. A signiﬁcance of 0.05 was
required for a variable to be included in the multi-
variate model, whereas 0.10 was the cutoff value for
exclusion. Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) were calculated. A p value <0.05 was
considered to be statistically signiﬁcant.
Baseline characteristics did not signiﬁcantly differ
between groups. PRU 1 h after the LD was 168
(interquartile range [IQR]: 61 to 251) and 252 (IQR: 167
to 301) in the crushed and integral groups, respec-
tively (p ¼ 0.006), with no differences observed at 2,
4, and 8 h (Figure 1). HPR was found in 14 (35%) and
26 (63%) patients at 1 h (p ¼ 0.011) and in 8 (20%)
and 11 (28%) patients at 2 h (p ¼ 0.431) in the
crushed and integral groups, respectively.
Independent predictors of HPR 1 h after LD were
morphine use (increased HPR) and crushed
ticagrelor tablet administration (decreased HPR).
Morphine-treated patients also showed higher 1-h
PRU values in the crushed ticagrelor group (p ¼
0.001). Adverse events were not increased by the
administration of crushed ticagrelor.
Our study shows, for the ﬁrst time to our knowl-
edge, that crushed ticagrelor tablet administration in
STEMI patients is feasible and provides earlier
platelet inhibition compared with standard integral
tablets. If this effect translates into fewer acute stent
thromboses and into better myocardial reperfusion, it
should be assessed in larger studies. All P2Y12 recep-
tor antagonists used at the present time in STEMI
treatment are only available orally. This is an impor-
tant limitation in patients with difﬁculties with
swallowing such as the elderly, those patients
with prior stroke or dysphagia, or those who have
been sedated or intubated. Our study might support
the use of crushed ticagrelor in patients unable to
swallow.
Our results must be evaluated in light of some
limitations. First, the small sample size is certainly
the most important limitation. However, we were
able to enroll a prospective homogenous population
of STEMI patients that mirrors other similar studies,
and clinical outcome data were reported only as
indicative. The safety proﬁle and patient tolerance
of crushed ticagrelor tablets should be deﬁnitively
tested in broader studies. Second, to conﬁrm
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Platelet reactivity was assessed at baseline, 1, 2, 4, and 8 h after a 180-mg ticagrelor loading dose in patients treated by crushed tablets
(diamonds) or integral tablets (squares). Data are expressed as mean  SD.
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512enhanced drug absorption, a pharmacokinetic
analysis could also have been performed. Higher
plasma levels of ticagrelor and its active metabolite
with crushed tablets as compared with integral
tablets have been recently reported in healthy
subjects (4). Finally, unmeasured confounder and
overﬁtting risks cannot be excluded in our
multivariable model.
These limitations notwithstanding, the present
study provides unique and potentially important
insights in the treatment of STEMI patients.*Guido Parodi, MD, PhD
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Suppl 12:A229.TGFbR1 Inhibition Blocks
the Formation of Stenosis
in Tissue-Engineered
Vascular GraftsWe previously developed a tissue-engineered vas-
cular graft (TEVG), created by seeding a biodegrad-
able scaffold with autologous bone marrow–derived
